AU1599301A - Modulating IL-13 activity using mutated IL-13 molecules that are antagonists or agonists of IL-13 - Google Patents

Modulating IL-13 activity using mutated IL-13 molecules that are antagonists or agonists of IL-13

Info

Publication number
AU1599301A
AU1599301A AU15993/01A AU1599301A AU1599301A AU 1599301 A AU1599301 A AU 1599301A AU 15993/01 A AU15993/01 A AU 15993/01A AU 1599301 A AU1599301 A AU 1599301A AU 1599301 A AU1599301 A AU 1599301A
Authority
AU
Australia
Prior art keywords
mutated
agonists
antagonists
modulating
molecules
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU15993/01A
Inventor
Bharat H. Joshi
Yasuo Oshima
Raj K Puri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of AU1599301A publication Critical patent/AU1599301A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5437—IL-13
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
AU15993/01A 1999-11-11 2000-11-10 Modulating IL-13 activity using mutated IL-13 molecules that are antagonists or agonists of IL-13 Abandoned AU1599301A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16523699P 1999-11-11 1999-11-11
US60165236 1999-11-11
PCT/US2000/031044 WO2001034645A2 (en) 1999-11-11 2000-11-10 Mutated il-13 molecules and their uses

Publications (1)

Publication Number Publication Date
AU1599301A true AU1599301A (en) 2001-06-06

Family

ID=22598038

Family Applications (1)

Application Number Title Priority Date Filing Date
AU15993/01A Abandoned AU1599301A (en) 1999-11-11 2000-11-10 Modulating IL-13 activity using mutated IL-13 molecules that are antagonists or agonists of IL-13

Country Status (4)

Country Link
EP (1) EP1263785A2 (en)
AU (1) AU1599301A (en)
CA (1) CA2404763A1 (en)
WO (1) WO2001034645A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010053371A1 (en) * 1999-01-07 2001-12-20 Waldemar Debinski Method for diagnosing, imaging, and treating tumors using restrictive receptor for interleukin 13
AU2001288405B8 (en) * 1998-04-03 2007-06-14 The Penn State Research Foundation Amino acid substitution mutants of interleukin 13
GB0105360D0 (en) * 2001-03-03 2001-04-18 Glaxo Group Ltd Chimaeric immunogens
WO2003016346A1 (en) * 2001-08-17 2003-02-27 Hitachi Chemical Co., Ltd. Ligands
JP2006501249A (en) * 2002-08-30 2006-01-12 グラクソ　グループ　リミテッド vaccine
AR041086A1 (en) * 2002-08-30 2005-04-27 Glaxo Group Ltd VACCINE
ES2343965T3 (en) 2003-11-25 2010-08-13 The Government Of The United States, As Represented By The Secretary Of Health And Human Services ANTI-CD22 ANTIBODIES AND MUTED IMMUNOCONGUJADOS.
JP4943161B2 (en) 2003-12-23 2012-05-30 ジェネンテック， インコーポレイテッド Treatment of cancer with a novel anti-IL13 monoclonal antibody
EP1877074B1 (en) 2005-04-15 2013-03-27 The Government of the United States of America, as represented by the Secretary of Health and Human Services Treatment and prevention of inflammatory bowel disease involving il-13 and nkt cells
ES2660026T3 (en) 2005-07-29 2018-03-20 The Government Of The United States Of America, As Represented By The Secretary Of Health And Human Services Exotoxins of mutated pseudomonas with reduced antigenicity
EP2475398B1 (en) 2009-09-11 2015-05-20 The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services Improved pseudomonas exotoxin a with reduced immunogenicity
RU2016107435A (en) 2013-09-13 2017-10-18 Дженентек, Инк. COMPOSITIONS AND METHODS FOR DETECTING AND QUANTITATIVE DETERMINATION OF THE PROTEIN OF CELLS-OWNERS IN CELL LINES AND RECOMBINANT POLYPEPTIDE PRODUCTS
NZ756749A (en) 2013-09-13 2022-05-27 Genentech Inc Methods and compositions comprising purified recombinant polypeptides
WO2015042706A1 (en) 2013-09-24 2015-04-02 Medicenna Therapeutics Pte Ltd Interleukin-4 receptor-binding fusion proteins and uses thereof
AU2015315110B2 (en) * 2014-09-09 2021-04-08 Glycosyn LLC Alpha (1,3) fucosyltransferases for use in the production of fucosylated oligosaccharides
EP3194446B1 (en) * 2014-09-18 2022-10-26 Cedars-Sinai Medical Center Compositions and methods for treating fibrosis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5696234A (en) * 1994-08-01 1997-12-09 Schering Corporation Muteins of mammalian cytokine interleukin-13
US5614191A (en) * 1995-03-15 1997-03-25 The United States Of America As Represented By The Department Of Health And Human Services IL-13 receptor specific chimeric proteins and uses thereof
US5710023A (en) * 1996-03-01 1998-01-20 Genetics Institute, Inc. IL-13 cytokine receptor chain
US6296843B1 (en) * 1998-04-03 2001-10-02 The Penn State Research Foundation Mutagenized IL 13-based chimeric molecules
WO2001025282A1 (en) * 1999-10-06 2001-04-12 The Penn State Research Foundation Il13 mutants

Also Published As

Publication number Publication date
EP1263785A2 (en) 2002-12-11
CA2404763A1 (en) 2001-05-17
WO2001034645A3 (en) 2002-03-07
WO2001034645A2 (en) 2001-05-17

Similar Documents

Publication Publication Date Title
AU2056800A (en) Heterocyclic piperidines as modulators of chemokine receptor activity
AU2056700A (en) 2-substituted-4-nitrogen heterocycles as modulators of chemokine receptor activity
AU1599301A (en) Modulating IL-13 activity using mutated IL-13 molecules that are antagonists or agonists of IL-13
AU2482100A (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
AU3126700A (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
AU2057200A (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
AU4520801A (en) Novel substituted phenanthridinones and methods of use thereof
IL149096A0 (en) Positive modulators of nicotinic receptor agonists
AU3867400A (en) Methods of using bioelastomers
AU2377000A (en) Methods of characterizing drug activities using consensus profiles
EP1432431A4 (en) Methods and compositions for modulating interleukin-21 receptor activity
AU2002326948A1 (en) Piperizinones as modulators of chemokine receptor activity
AU3311199A (en) Melanocortin receptor antagonists and modulations of melanocortin receptor activity
AU3386400A (en) 3-alkyl substituted pyrrolidine modulators of chemokine receptor activity
AU2001274817A1 (en) Agents that modulate dna-pk activity and methods of use thereof
AU1201401A (en) Benzylcycloalkyl amines as modulators of chemokine receptor activity
AU2001230704A1 (en) Pyrimidine compounds and their use as modulators of chemokine receptor activity
IL149098A0 (en) Positive modulators of nicotinic receptor agonists
AU5009200A (en) Novel beta-secretase and modulation of beta-secretase activity
AU7599200A (en) Fractal analysis of time varying data
AU3623700A (en) Apoptosis inducing molecule ii and methods of use
AU5328500A (en) N-cyclopentyl modulators of chemokine receptor activity
AU5322900A (en) Modulation of protein levels using the scf complex
AU1929301A (en) Methods of use of peptide deformylase inhibitors as novel antibacterial agents
AU1242800A (en) Isolated vshk-1 receptor polypeptides and methods of use thereof

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase